Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.
A higher percentage of Black patients had elevated erythrocyte sedimentation rate, C-reactive protein, and hip involvement in a small study. Black patients also had higher grades of sacroiliitis.
A pilot study finds longer delays (more than 4 years) were associated with history of uveitis, ankylosing spondylitis at diagnosis, and being in the most vulnerable socioeconomic group.
DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.“Current therapies are not rooted in a thorough understanding of disease pathogenesis,” Joerg Ermann, MD, assistant professor of medicine in the division of rheumatology,